Aktienanalyse zu Aptevo Therapeutics Inc (APVO)APVOAptevo Therapeutics Inc

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aptevo Therapeutics is not a good buy right now due to its extremely low RSI of 19.049, indicating oversold conditions, and a staggering year-to-date change of -86.80%. The stock has significant financial challenges, including a reported EPS of -40.11, which is far below expectations. The main risk is its forward P/E of 3.8895, which suggests that while the stock may be undervalued, the company is struggling to generate revenue, as evidenced by total revenue of $0.00 for multiple quarters. The lack of positive cash flow and ongoing losses indicate that investors should be cautious before considering a purchase.

1 analysts cover APVO: 1 rate it Buy, 0 Hold and 0 Sell.